Abstract 1590P
Background
International studies have highlighted the poor outcomes associated with cancer diagnosis following an emergency presentation (EP) to hospital. This study aims at assessing the rate of cancer patients newly referred to the Greater Paris University Hospitals (APHP) after an EP and the impact of EP on patient survival across various types of cancer.
Methods
A retrospective multicenter cohort study was conducted using the data warehouse of APHP. Consecutive patients newly referred with breast, lung, colon, rectum or pancreatic cancer between January 2019 and June 2022 were identified using claims data (ICD-10 codes). Comparative analyses between EP (diagnosis confirmed ≤30 days after emergency admission) and non-EP patients comprised in-hospital imaging, initial tumor staging from baseline PET/CT and CT-scan reports, and surgical treatment. Multivariable logistic regression was used to assess EP prevalence and its association with patient survival, adjusting for age, gender, diagnostic year (considering potential impacts of the COVID-19 pandemic), and cancer site. A Cox model was used to assess association of EP with survival, adjusting for the same factors and baseline metastatic status.
Results
The final cohort comprised 25,845 patients with 3,960 (15.3%) newly referred after an EP. EP patients exhibited higher rates of metastatic cancer (59% vs. 45%) and in-hospital imaging (53% vs. 31%), lower surgery rates (except for colon cancer patients) (18% vs 41%), and a higher risk to die within a year of diagnosis (49% vs 16%). Lung and pancreatic cancers were more frequent in EP than other cancer sites (20% and 23% respectively). The proportion of EP and non-EP patients was comparable during and after the COVID-19 pandemic, except for lung cancer. In the multivariable analysis, EP was strongly associated with age only for patients above 80 years of age (odds ratio: 3.1, 95% CI; 2.6-3.6). After adjusting for age and cancer site, patient mortality rate increased with EP referral (HR: 2.7, 95% CI 2.5-2.8).
Conclusions
Emergency presentation in a university hospital is a marker of poor outcome among newly referred cancer patients. Better coordination between hospitals and ambulatory health care networks is needed.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1594P - Cancer mortality in young population and estimated radon areas in Spain
Presenter: Miquel Ferriol-Galmés
Session: Poster session 10
1598P - Xaluritamig, a STEAP1 x CD3 XmAb 2+1 immune therapy, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Initial results from dose expansion cohorts in a phase I study
Presenter: William Kelly
Session: Poster session 10
1600P - Phase II trial of pembrolizumab and lenvatinib in advanced neuroendocrine prostate cancer (NEPC)
Presenter: Ulka Vaishampayan
Session: Poster session 10
1601P - First results from ZZFIRST: A randomized phase II trial of enzalutamide (EZ) with or without talazoparib (TALA) in metastatic hormone-naïve prostate cancer (mHNPC)
Presenter: Joaquin Mateo
Session: Poster session 10
1602P - CBP-1018, Bi-ligand-drug conjugate (Bi-XDC) drug treated for metastatic castration resistant prostate cancer (mCRPC) patients from phase I study results
Presenter: Kaiwen Li
Session: Poster session 10
1603P - Updated safety and efficacy of tazemetostat (TAZ) plus enzalutamide (ENZ) in patients with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Wassim Abida
Session: Poster session 10
1604P - PSMA-targeted radioligand therapy (RLT) with 131I-LNTH-1095 (1095) plus enzalutamide (enza) vs enza alone in chemotherapy-naïve patients (pts) whose piflufolastat F 18-avid metastatic castration-resistant prostate cancer (mCRPC) progressed on abiraterone (abi): ARROW
Presenter: Evan Yu
Session: Poster session 10
1605P - Opevesostat (MK-5684/ODM-208), an oral CYP11A1 inhibitor, in metastatic castration-resistant prostate cancer (mCRPC): Updated CYPIDES phase II results
Presenter: Karim Fizazi
Session: Poster session 10
1606P - Mature follow up of phase I dose finding trial of pembrolizumab (pembro) with AR inhibitors (ARI) and priming tumour-targeted radiation with anti-PSMA alpha emitter 225Ac-J591
Presenter: Aaron Holmes
Session: Poster session 10